Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy

AIDS Research and Human Retroviruses

Volumn 16, Issue 6, 2000, Pages 529-537

  Van Vaerenbergh, K ^a   Van Laethem, K ^a   Van Wijngaerden, E ^a   Schmit, J C ^b   Schneider, F ^b   Ruiz, L ^c   Clotet, B ^c   Verhofstede, C ^d   Van Wanzeele, F ^d   Muyldermans, G ^e   Simons, P ^e   Stuyver, L ^f   Hermans, P ^g   Evans, C ^h   De Clercq, E ^a   Desmyter, J ^a   Vandamme, A M ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e AIDS Referentie Laboratorium   (Belgium)

^f INNOGENETICS   (Belgium)

^g SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^h Murex   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MUTATION; PREDICTION; PRIORITY JOURNAL; VIRUS LOAD;

EID: 0034630185     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922200308945     Document Type: Article

References (38)

1. Schinazi RF, Larder BA, and Mellors JW: Mutations in retroviral genes associated with drug resistance: 1999-2000 update. Int Antiviral News 1999;7:46-49.
2. Larder BA, Darby G, and Richman DD: HIV with reduced sensitivity to zidovudine (AZT) related during prolonged therapy. Science 1989;243:1731-1734.
3. Boucher CAB, O'Sullivan E, Mulder JW, et al.: Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992;165:105-110.
4. Schuurman R, Nijhuis M, van Leeuwen R, et al.: Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995;171:1411-1419.
5. Craig C and Moyle G: The development of resistance to HIV-1 to zalcitabine. AIDS 1997;11:271-279
6. Vandamme AM, Van Laethem K, and De Clercq E: Managing resistance to anti-HIV drugs. Drugs 1999;57:337-361.
7. D'Aquila RT, Johnson VA, Welles SL, et al.: Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995;122:401-408.
8. Montaner JSG, Singer J, Schechter MT, et al.: Clinical correlates of in vitro HIV-1 resistance to zidovudine. Results of the Multi-centre Canadian AZT Trial. AIDS 1993;7:189-196.
9. Tudor-Williams G, St Clair MH, McKinney RE, et al.: HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet 1992;339:15-19.
10. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, and Merigan TC: A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis 1993;167:526-532.
11. Schmit JC, Ruiz L, Clotet B, et al.: Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996;10:995-999.
12. Hirsch MS, Conway B, D'Aquila RT, et al.: Antiretroviral drug resistance testing in adults with HIV infection. JAMA 1998;279: 1984-1989.
13. Vandamme AM, Van Vaerenbergh K, and De Clercq E: Anti-HIV drug combination strategies. Antiviral Chem Chemother 1998;9: 187-203.
14. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-1300.
15. Wong JK, Hezareh M, Günthard HF, et al.: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-1295.
16. Wong JK, Ignacio CC, Torriani F, Havlir D, Fitch NJS, and Richman DD: In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol 1997;71:2059-2071.
17. Chun TW, Carruth L, Finzi D, et al.: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (London) 1998;387:183-188.
18. Günthard HF, Wong JK, Ignacio CC, et al.: Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998;72:2422-2428.
19. Carpenter CJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society - USA panel. JAMA 1998;280(1): 78-86.
20. Van Laethem K, Van Vaerenbergh K, Schmit JC, et al.: Phenotypic assays and sequencing are less sensitive for the detection of resistance in mixed genotypes compared to point mutaton assays. J AIDS 2000 1999;22(2):107-118.
21. Stuyver L, Wyseur A, Rombout A, et al.: Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother 1997;41:284-291.
22. St. Clair MH, Martin JL, Tudor-Williams G, et al.: Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991;253:1557-1559.
23. Schinazi RF, Lloyd RM, Nguyen MH, et al.: Characterization of human immunodeficiency viruses resistance to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993;37:875-881.
24. Najera I, Richman DD, Olivares I, et al.: Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type I isolates. AIDS Res Hum Retroviruses 1994;10:1479-1488.
25. Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, De Groot T, and Boucher C: World-wide evaluation of DNA sequencing approaches for the identification of drug resistance mutations in the HIV-1 reverse transcriptase. in: 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998. [Abstract 532]
26. Vandamme AM, Witvrouw M, Pannecouque C, et al.: Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs. In: Methods in Molecular Medicine, Volume 24: Antiviral Methods and Protocols (Kinchington D and Schinazi RF, eds.). Humana Press, Totowa, NJ, 2000, pp. 223-258.
27. Rey D, Hughes M, Pi JT, et al.: HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: Immunologic and virologic responses to zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17(3):203-208.
28. Schmit J-C, Cogniaux P, Hermans C, et al.: Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J Infect Dis 1996;174:962-968.
29. Larder B : New insights into genetic mechanisms of drug resistance. In: 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4, 1999. [Abstract S34]
30. Schmit J-C, Van Laethem K, Ruiz L, et al.: Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS 1998;12:2007-2015.
31. Gómez-Cano M, Rubio A, Puig T, et al.: Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS 1998;12:1015-1020.
32. Van Vaerenbergh K, Van Laethem K, Albert J, et al.: Prevalence of the multidrug resistant 6 bp insert at RT codon 69 among European HIV-1-infected patients receiving various combinations of nucleoside analogues. In: Third International Workshop on HIV Drug Resistance and Treatment Strategies, San Diego, June 23-26, 1999. [Abstract 148]
33. Delaney S, Zheng N, McQueen PW, et al.: Emergence of drug-resistant HIV-1 from patients on long term ddI therapy. In: 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998. [Abstract 41224]
34. Vidal C, Garcia F, Gatell JM, et al.: Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naïve HIV-1 infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19(1):55-60.
35. Zalopa A, Shafer R, Warford A, et al.: HIV genotypic predictors of antiviral response to saquinavir/ritonavir therapy in patients who failed prior protease inhibitors (PIs): A clinical cohort study. In: 12th World AIDS Conference, Geneva, June 28-July 3, 1998. [Abstract 32287]
36. Mellors J: Review of Lago Maggiore Resistance Meeting. In: 12th World AIDS Conference, Geneva, June 28-July 3, 1998. [Oral Presentation 227]
37. Durant J, Clevenbergh P, Halfon P, et al.: Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. Lancet 1999;353(9171):2195-2199
38. Baxter JD, Mayers DL, Wentworth DN, et al.: Final results of CPCRA 046: A pilot study of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. In: Third International Workshop on HIV Drug Resistance and Treatment Strategies, San Diego, June 23-26, 1999. [Abstract 61]